Gonadorelin Acetate Research Peptide

Gonadorelin is the synthetic version of gonadotropin-releasing hormone, a ten-amino-acid peptide made in the hypothalamus. Its sequence is identical to the natural hormone, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2. In laboratory research it is used to study the GnRH receptor, pituitary gonadotrope cells and the release of LH and FSH in cell and animal models.

Yes, for practical purposes. GnRH and LHRH are two names for the same natural hormone; LHRH reflects the early focus on luteinising hormone, while GnRH acknowledges that it releases FSH as well. Gonadorelin is the official non-proprietary name for the synthetic peptide with that sequence. GnRH-I is used to separate it from GnRH-II, a related form that differs at three positions.

Leuprorelin and triptorelin are synthetic analogues built on the gonadorelin sequence. Both replace the glycine at position six with a D-amino acid, and leuprorelin also swaps the final glycinamide for an ethylamide group. These changes slow breakdown and increase binding, so the analogues act for much longer. Gonadorelin keeps the native sequence, which is why it is used as the natural reference ligand.

Both ends of gonadorelin are chemically capped. “pGlu” is pyroglutamic acid, a glutamine or glutamate that has closed into a ring, so the chain has no free amino group at the start. “-NH2” shows that the final glycine is an amide rather than an acid. Both features help the hormone bind its receptor and resist some enzymes that trim peptide ends.

Most G protein-coupled receptors have an intracellular tail that the cell uses to switch them off and pull them inside. The mammalian GnRH receptor, cloned in 1992, has no such tail. Researchers study this because it changes how the receptor responds to repeated stimulation, and it makes the receptor a useful model for comparing desensitisation mechanisms across the receptor family.

They act at neighbouring steps of the same pathway. Kisspeptin is released onto GnRH neurons in the hypothalamus and makes them release GnRH; GnRH then acts on the pituitary. Kisspeptin-10 is therefore studied at the level of the brain, while gonadorelin is used to stimulate the pituitary directly, bypassing the neurons above it.

Yes. Gonadorelin has been licensed as a prescription medicine in a number of countries, most often as a diagnostic test of how well the pituitary can release gonadotropins. It has also been authorised as a veterinary medicine for cattle. The material sold by Crown Peptides is a research compound and is not a medicinal product.

In the 1978 rhesus monkey study, hourly pulses of synthetic GnRH restored LH and FSH release in animals whose own GnRH had been switched off, while a constant infusion did not. Moving animals from pulses to continuous delivery shut the response down again. The pituitary appears to need gaps between signals, and steady exposure leads to desensitisation.

Through the speed of its pulses. In GnRH-deficient rats, pulses every 30 minutes mainly increased transcription of the LH-beta gene, while pulses every four hours gave a sustained rise in FSH-beta transcription. The FSH response tracked follistatin, a pituitary protein that rose with fast pulses and fell with slow ones, so pulse frequency acts as a code the gonadotrope reads.

In the developing nose. Tracer work in fetal mice showed that GnRH neurons arise in the medial olfactory placode and travel into the forebrain along the nervus terminalis, a small cranial nerve, before reaching the hypothalamus. This migration is studied in models of Kallmann syndrome, where it fails and both gonadotropin release and the sense of smell are affected.

It linked kisspeptin directly to GnRH neurons. The kisspeptin receptor was found on GnRH neurons in mice, kisspeptin did not raise LH or FSH in mice lacking that receptor, and in sheep kisspeptin given into the brain released GnRH into the cerebrospinal fluid, followed by a rise in LH. Gonadorelin is the hormone measured at that step.

Gonadorelin is not a controlled drug under the Misuse of Drugs Act 1971, and it does not appear on the Class C list of anabolic steroids and related hormones. It is, however, the active ingredient in a UK-licensed prescription-only medicine, Gonadorelin 100 micrograms powder for solution for injection, used as a pituitary function test, and in veterinary medicines authorised for cattle. Crown Peptides supplies gonadorelin acetate only as a research compound for laboratory use, not as a medicine. This is general information, not legal advice.

Gonadorelin Acetate is coming soon to Crown Peptides in 2mg vials, available singly or in packs of 3, 5 or 10 with a saving on every vial. Orders ship from the UK, and every batch is independently tested, with its Certificate of Analysis published on this page once stock arrives.

Two milligrams of a 1,182-dalton peptide is roughly 1.7 micromoles, or about 1.6 micromoles if calculated on the monoacetate salt; the exact peptide content is given on the batch’s Certificate of Analysis. Pituitary cell studies typically use GnRH at nanomolar concentrations, so one vial covers a good deal of in vitro work, and the multi-vial packs keep a longer pulse study on a single batch.

Keep the unreconstituted powder at -20°C ± 5°C, dry and away from light. The sequence contains tryptophan and tyrosine, both of which are sensitive to light and oxidation, so vials are best kept sealed and dark until use. Prepared solutions should follow storage conditions validated for your study design, and each batch’s Certificate of Analysis documents the material as dispatched.